Compared side by side

CagriSema vs semaglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

CagriSema is semaglutide plus cagrilintide, a long-acting analogue of the fullness hormone amylin, in one weekly regimen; amylin and GLP-1 curb appetite through partly different routes, so their effects add up. In its main trial people on CagriSema lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone. Semaglutide is FDA-approved, as Ozempic and Wegovy; CagriSema isn’t approved yet, and Novo Nordisk filed it with the FDA in December 2025.

Side by side

ComparedCagriSemaSemaglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asCagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + SemaOzempic, Wegovy
What it isTwo weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic.A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
How it worksWeekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026.GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
Commonly reportedStrong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet.The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
Studied rangeResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.FDA label: 0.25–2.4 mg, starting dose 0.25 mg.
How oftenWeeklyWeekly SubQ
Half-life~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial)~1 week (FDA label)
RouteSubQ injectionSubQ injection
Typical runStudied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025.FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, abdominal painNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking CagriSema or semaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

CagriSema

  • Day 1–28 · 0.25 mg The 0.25 mg start
  • Day 29–364 · 0.5 mg 0.5 mg of each
  • Day 57–364 · 1 mg 1 mg of each, halfway up
  • Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
  • Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose

Every card for CagriSema, with its sources

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Questions people ask

How long do CagriSema and semaglutide last?

The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of semaglutide is ~1 week (FDA label).

How often are CagriSema and semaglutide taken?

CagriSema: weekly. Route: SubQ injection. Semaglutide: weekly SubQ. Route: SubQ injection.

How are CagriSema and semaglutide dosed in research?

The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose.

What are the common side effects of CagriSema and semaglutide?

For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For semaglutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk.

Each one in full

Track it in the app

PepVault for iPhone

Taking CagriSema or semaglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo